Nuevolution Technology Progress: Nuevolution scales its compound collection to 40 trillion using its Chemetics™ drug discovery platform

Stockholm, 14 February 2017. Nuevolution AB (publ) (NUE.ST) today announced the successful production and validation of its new ultra-high complexity library of 40 trillion (40,000,000,000,000) compounds. This library is roughly 10,000 fold larger than Nuevolution’s previous libraries, and likely constitutes the largest synthetic compound collection in the world.

The 40 trillion (40T) library was assembled from the use of tens of thousands of individual fragments (building blocks) introducing an unprecedented chemical diversity.

This library was produced with a key focus on hit identification for the many important and very tough-to-drug therapeutic targets not easily addressed by other approaches. The first 40T screening against a small subset of such difficult targets have identified both novel compound scaffolds and compounds with picomolar potency (extreme and very unusual potency) for their target, directly from the library without any further optimization performed.

“The result demonstrates the great power of our Chemetics™ drug discovery platform. It supports both the growing Nuevolution pipeline and discovery programs for current and future collaboration partners”, said Dr. Thomas Franch, CSO, and continued: “The 40T library has been in the making for about two years, and we are very pleased by now being able to bring this extraordinary library into service in our search for novel and innovative medicines”.


For more information, please contact:

Thomas Franch, CSO
Phone: +45 7020 0987

Henrik D. Simonsen, CFO
Phone: +45 3913 0947

 About Chemetics™

The Nuevolution Chemetics™ platform technology comprises proprietary methods enabling DNA-encoding of compound libraries for fast and cost efficient screening of disease targets. Nuevolution annually produces up to eight Chemetics™ libraries. For further details see Nuevolution homepage:

About Nuevolution
Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, headquartered in Copenhagen, Denmark. Nuevolution partners its proprietary discovery platform and programs with pharmaceutical and biotechnology companies to seek
future benefit for patients in need of novel medical treatment options. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.

This information is information that Nuevolution AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was sent for publication, through the agency of the contact persons set out above, on Tuesday 14 February 2017, 13:00 CET.
Nuevolution AB (publ) is listed at Nasdaq First North Premier in Stockholm, Sweden (ticker: NUE.ST). Redeye AB acts as Certified Adviser to Nuevolution AB (publ). More information about Nuevolution can be found at: